Industry verticals
Warm Introductions in Healthcare and Medical Device Sales
Medical device sales operates through a procurement architecture unlike any other commercial context. GPOs control pricing access. IDNs gate system-wide formulary approval. Value Analysis Committees evaluate clinical evidence before a device reaches a surgeon’s hands. Navigating this structure requires warm introductions, not just to clinical users, but to the procurement chain that controls access. Four introduction mechanics that determine how devices reach clinical adoption.
Why direct access fails in medical device sales
Medical device sales representatives occupy a paradox: they need to reach the physicians who use their products, but those physicians are surrounded by institutional layers specifically designed to limit unsolicited commercial contact. IQVIA tracking data has documented a long-run decline in HCP accessibility to pharmaceutical and device field teams. In hospital settings, many physicians at academic medical centres and major IDNs are classified as access-restricted, seeing fewer than a quarter of the representatives who attempt to contact them.
The access restrictions are not arbitrary. Credentialing systems like Reptrax and Vendormate require representatives to register and schedule in advance. OR and cath lab access requires sterile-field compliance training. Institutional conflict-of-interest policies at academic medical centres restrict what relationships employed physicians can hold with industry. And above the clinical layer sits the procurement architecture of GPOs, IDNs, and Value Analysis Committees that controls whether a device reaches clinical use at all, independent of whether the physician wants to use it.
The introduction channel works in this environment because it bypasses the commercial access layer entirely. A peer physician who knows the technology and knows the colleague introduces the device in a scientific context: a conversation after a society presentation, a post-proctoring debrief, a hallway exchange at a skills lab. That interaction is not a commercial contact. It carries the credibility of peer judgment, not manufacturer promotion.
The procurement chain: GPOs, IDNs, and Value Analysis Committees
Before a device reaches clinical use in a hospital system, it typically needs to pass through three procurement layers. Understanding where warm introductions matter at each layer is the strategic challenge in medical device BD.
Group Purchasing Organizations (GPOs)
GPOs aggregate purchasing volume across hundreds or thousands of member hospitals to negotiate contract pricing with device manufacturers. GPO contracts, awarded through a formal RFP process, determine which devices are available at contracted pricing to member facilities. Without a GPO contract, a device company must sell at list price or negotiate directly with each hospital, which is commercially unworkable at scale. Getting onto a GPO contract requires demonstrating clinical differentiation and cost-effectiveness to the GPO’s clinical and contracting committees, not just to the end user. Warm introductions to GPO clinical review staff or to member-hospital advocates who serve on GPO advisory panels can determine whether a company secures a category contract.
Introduction angle: Introductions to GPO clinical committee members or to hospital supply chain directors who have GPO advisory influence. A peer hospital CSO or department director who has already evaluated and deployed the device is the strongest possible reference for a GPO committee deliberation.
Integrated Delivery Networks (IDNs)
IDNs are health systems that operate multiple hospitals, clinics, and ancillary facilities under a single administrative and purchasing umbrella. A system-wide IDN contract can cover dozens of facilities simultaneously, which makes IDN approval far more valuable than single-hospital approvals. IDN purchasing authority is typically centralised: a system-level supply chain team negotiates contracts, and a Value Analysis Committee evaluates clinical evidence before a device gains system-wide formulary approval. Decisions are made at the system level, but clinical input flows upward from the facility level through department heads and service-line directors.
Introduction angle: Introductions to IDN system-level supply chain directors, to clinical service-line leaders who sit on VAC review panels, or to department heads at flagship facilities within the IDN who carry disproportionate influence in system-wide evaluations.
Value Analysis Committees (VACs)
VACs are the clinical decision-making bodies within hospital systems that evaluate whether a new device should be added to the formulary, replace an existing device, or be considered for system-wide rollout. VAC composition typically includes physicians in the relevant specialty, nursing and clinical staff representatives, a supply chain or contracting representative, and sometimes a quality or patient-safety officer. The VAC process is evidence-based: vendors are expected to submit clinical data, health economic analysis, and peer evidence. The key point is that VAC deliberations are peer-shaped: clinical members’ opinions carry weight, and a physician who has personal experience with the device and is willing to present that experience to the committee is the most effective advocate a device company can have.
Introduction angle: Introductions to physicians who will serve as clinical champions in the VAC process. The champion does not merely endorse the device. They present clinical data, answer peer questions, and advocate for formulary inclusion. Identifying and cultivating this champion relationship, usually through a peer introduction from an existing KOL or society colleague, is the central warm-introduction challenge in medical device BD.
The clinical champion model
Unlike in pharmaceutical sales, where a prescription decision is the physician’s individual clinical act, device adoption, particularly for capital equipment, implantables, and procedural technologies, requires a physician who will actively advocate for the device within the hospital system. This is the clinical champion: the surgeon or interventionalist who will present the device to the VAC, train colleagues on the technique, and stake their clinical credibility on the recommendation. The champion relationship is the central warm-introduction challenge in medical device commercial strategy.
Identifying the right clinical champion
The surgical or procedural champion is not simply the most senior physician in a department. The effective champion is a physician who is technically curious, has institutional credibility with peers, sits on or has access to the VAC, and is willing to invest time in the evaluation and advocacy process. These characteristics do not always co-reside. In practice, device companies identify potential champions through publication records in the relevant specialty, trial investigator roles, society leadership (for example, serving on an American Heart Association or Society of Thoracic Surgeons guidelines committee), and peer nomination, asking respected KOLs to name colleagues who they believe are both clinically progressive and institutionally connected.
The peer introduction to a champion
Direct outreach from a device company to an unsolicited physician carries low trust signal: the physician knows the commercial motivation and is appropriately sceptical about clinical claims from a manufacturer’s representative. A peer introduction from a trusted colleague who has personal procedural experience with the device is structurally different. The colleague is vouching not just for the company but for the technology’s clinical performance in their own hands. This converts a cold commercial contact into a peer scientific conversation, the same mechanism Granovetter’s network brokerage research describes, applied to the clinical adoption context. The introduction typically happens at a professional society meeting, in a post-presentation conversation at a conference symposium, or through a structured peer-to-peer exchange organised by the manufacturer’s medical affairs team within compliance guardrails.
Proctoring as a warm-introduction amplifier
Medical device adoption in procedural specialties (cardiac, orthopaedic, neuro-intervention, robotic surgery) typically involves a training and proctoring phase in which an experienced operator, often a KOL at a high-volume centre, assists a new adopter through their first cases with a device. The proctor relationship is simultaneously a clinical mentorship and an implicit endorsement: the proctor’s willingness to travel and assist communicates peer confidence in the technology. Device companies facilitate proctoring relationships through their KOL network, and the proctor introduces the new adopter not just to the technique but to the community of practice around the device. This extends the warm-introduction network with each proctored case.
Conference and skills lab introductions
Specialty society meetings and procedural training events are the primary contexts in which medical device introduction relationships are built. The structural reason is compliance: company-sponsored dinners and direct-to-physician outreach have progressively tightened under AdvaMed guidelines and hospital COI policies, while peer-to-peer scientific exchange at educational events remains largely unconstrained. The conference environment places physicians and their peers in a common frame of reference (they are there to evaluate and discuss technology), which makes introductions both natural and high-conversion.
Specialty society annual meetings
American College of Cardiology (ACC), Radiological Society of North America (RSNA), American Academy of Orthopaedic Surgeons (AAOS), European Association of Urology (EAU)
Society annual meetings are the primary forum where device KOLs present data and interact with peers. Exhibition hall booth presence lets field teams facilitate introductions between existing customers and interested prospects. Satellite symposia (scientific sessions sponsored by the company but organised around peer-presented data) create a compliant context for KOL-to-peer introduction: the presenting physician speaks from clinical experience, not as a company spokesperson, and attendee physicians can follow up directly.
Trade-facing industry meetings
Medical Device + Manufacturing (MD&M) West, HIMSS (health IT), DeviceTalks
These events bring device industry professionals (BD, marketing, regulatory, manufacturing) together, not primarily clinicians. The warm-introduction opportunity is on the commercial and partnership side: connecting with hospital system supply chain executives, GPO contracting staff, distributor principals, and potential strategic partners. A GPO contracting director met through a mutual distributor contact is a warm introduction that would be difficult to create through cold outreach.
Surgical skills labs and cadaveric training courses
Wet labs at medical education centres, device company-sponsored hands-on training events at anatomy labs
Cadaveric labs and surgical skills sessions are among the most intimate and high-conversion contexts in medical device education. Participants are self-selected: only physicians who are genuinely curious about a technique attend. The faculty presenting, typically high-volume KOLs with direct procedural experience, interact with participants in a low-pressure educational environment. These interactions convert easily into warm introductions: a faculty member who knows a colleague’s clinical profile can make a direct, specific peer connection at the bench rather than in a crowded exhibition hall.
The distributor channel as an introduction network
Medical device companies, particularly in orthopaedics, surgical instruments, and diagnostics, sell substantially through independent distributors or exclusive field agencies rather than direct employed sales forces. Distributors are not passive order-takers. An experienced orthopaedic device distributor with a thirty-year relationship with the surgeons in their territory is a warm-introduction network in themselves: they know which surgeons are early adopters, who sits on the hospital’s VAC, which service-line director has the budget authority, and who the respected peer voices are within that clinical community.
Manufacturer-to-distributor introductions work in reverse too: a device company that can introduce a strong regional distributor to a hospital system where they don’t yet have a relationship (because the manufacturer’s existing customer at a flagship hospital in the same IDN can vouch for the company’s field support quality) creates introduction value that flows downstream into the distributor’s territory building. The warm-introduction network in medical device sales is bidirectional.
The compliance framework
The introduction mechanics described above operate within a compliance framework that differs in important ways from general B2B markets. Healthcare introductions that involve any financial component, such as consulting fees for KOLs, speaking honoraria, or sponsored symposia, must be structured to meet the requirements of the Anti-Kickback Statute, the Sunshine Act, and the AdvaMed code. The framework does not prohibit physician-industry relationships; it structures them.
Anti-Kickback Statute (AKS)
United StatesThe AKS (42 U.S.C. § 1320a-7b(b)) prohibits knowingly offering or paying anything of value to induce referrals of items or services covered by federal health care programs (Medicare, Medicaid). In the device context, this means that consulting fees, speaker honoraria, research funding, meals, travel, and entertainment provided to physicians who could influence the selection or ordering of a device must fall within a statutory safe harbour. Safe harbours exist for bona fide employment, personal services and management contracts (at fair market value, in writing, for legitimate services), and investment interests meeting specified criteria. The AKS is a criminal statute (violations carry fines and potential imprisonment), which is why device companies’ medical affairs and legal functions are deeply involved in structuring any physician relationship that has a financial component.
Physician Payments Sunshine Act / Open Payments
United StatesEnacted as part of the Affordable Care Act, the Sunshine Act requires applicable manufacturers of medical devices, as well as drugs, to track and report all transfers of value to covered recipients (physicians, dentists, and teaching hospitals) annually to CMS. The Open Payments database publishes this data publicly. Transfers of value include meals, consulting fees, speaker fees, royalties, travel, and research funding. Device companies and the physicians they work with are aware that all payments are public: a physician with large Open Payments entries from a single manufacturer invites scrutiny about the independence of their clinical recommendations. This does not prohibit the payments, but it shapes how clinical champions think about the profile they present publicly.
AdvaMed Code of Ethics
United States (voluntary; widely adopted)The Advanced Medical Technology Association code governs interactions between medical technology companies and healthcare professionals. It covers consulting arrangements, educational grants, research funding, co-development relationships, and items of educational value. The AdvaMed code standards for fair market value, legitimate purpose, and documentation closely parallel the PhRMA code for pharmaceuticals. Most major device companies require AdvaMed compliance as a condition of physician engagement, and hospital ethics offices increasingly audit physician-industry relationships against the code. In Europe, MedTech Europe publishes an equivalent code that applies across member companies.
Hospital conflict-of-interest policies
Institutional (varies by system)Beyond statutory and industry code requirements, academic medical centres and major health systems increasingly maintain their own conflict-of-interest policies that restrict the types of industry relationships their employed physicians may hold. Some systems prohibit physicians from serving on speaker bureaus; others cap consulting income or require institutional approval for industry-sponsored research. Device companies and their KOLs must navigate these institutional requirements in addition to statutory ones. Understanding the specific COI policy at a target institution is necessary before proposing a formal relationship with a physician at that system.
The practical implication is that device companies maintain dedicated medical affairs and compliance functions specifically to structure KOL and physician engagement programmes. An introduction that is made through a speaker programme, a clinical advisory board, or a research collaboration must be managed through these functions, not improvised by the field team. Understanding the compliance guardrails before proposing a physician relationship is a prerequisite for building the warm-introduction network in this sector.
What a medical device introduction brief looks like
The forwardable brief that a physician champion sends when introducing a device company to a colleague differs in structure from a commercial B2B introduction. The clinical relevance must lead: why is this technology clinically meaningful in this physician’s specific practice context? What patient population or procedural situation does it address? A brief that leads with commercial framing (market size, revenue potential) will fail the clinical credibility test.
A high-quality device introduction brief from a clinical champion typically includes: the specific procedural context in which the champion has used the device; a direct characterisation of their clinical outcome experience; a concrete statement of which patient population or technique the device addresses; and a specific ask (attending a demonstration case, reviewing a data summary, or connecting with the company’s clinical affairs team). The more specific the clinical context, the higher the trust transfer. A vague “this company has an interesting device in your space” carries almost no weight from a peer, while “I used this in three mitral valve cases last quarter and want to walk you through the data” is a compelling invitation.
The Granovetter network brokerage mechanism operates here in its healthcare-specific form: the bridge physician who knows both the KOL and the new potential adopter, and who can translate clinical experience across the gap between them, is where the introduction value is created. That bridge is the warm-introduction asset the device company is ultimately trying to cultivate.
FAQ
Medical device warm introduction FAQs
How is medical device warm introduction different from pharmaceutical warm introduction?
The mechanics overlap (both rely on KOL-to-peer and peer-to-physician trust transfer), but the procurement context is structurally different. Pharmaceutical adoption is primarily prescription-driven: the physician’s decision to prescribe a drug goes through a formulary and payer system but is ultimately the physician’s individual clinical choice. Medical device adoption, particularly for capital equipment and implantables, typically requires institutional approval through a Value Analysis Committee and either a GPO or IDN contract. This means the introduction target is often not only the clinical user but also the procurement and supply chain decision-makers who control formulary access. The proctoring relationship, where an experienced device user mentors a new adopter through their first cases, is also more structurally prominent in procedural device adoption than in pharma.
What is a KOL in medical device sales, and why do they matter?
A Key Opinion Leader (KOL) in medical device sales is a physician or clinical researcher with significant peer influence in a specific procedural domain: for example, an interventional cardiologist who chairs a major society’s device committee, a robotic surgeon who co-authored the technique’s landmark papers, or an orthopaedic surgeon who sits on an AAOS guidelines working group. KOLs matter because their peer endorsement carries trust weight that manufacturer representatives cannot replicate. When a KOL presents data at a society meeting or discusses a device with a colleague after a proctoring case, that communication is peer-to-peer scientific exchange, not a commercial contact. Physicians trust the clinical judgement of a respected colleague who has used the device in practice far more than they trust clinical claims from a manufacturer’s team.
What is a Value Analysis Committee, and how do warm introductions affect its decisions?
A Value Analysis Committee (VAC) is the clinical governance body within a hospital or health system that evaluates new devices before authorising formulary inclusion or system-wide use. VAC members include physicians in the relevant specialty, nursing staff, supply chain representatives, and sometimes quality and finance officers. VAC decisions are evidence-based (manufacturers typically submit clinical data packages), but the deliberation is peer-shaped: a clinical champion on the VAC who has personal experience with the device and advocates for it carries significant weight. Warm introductions matter because they are how device companies identify and cultivate the physician who will serve as that champion. A physician who was introduced to the device through a trusted colleague’s peer recommendation is more likely to develop the advocacy relationship than one who was cold-called by a field representative.
How do GPOs affect warm introduction strategy for medical device companies?
GPOs (Group Purchasing Organizations) aggregate the purchasing power of member hospitals and negotiate standardised contracts with device manufacturers. Without a GPO contract, a device must be sold outside the contracted pricing programme, which creates a cost and administrative burden that makes hospital adoption significantly harder. Getting onto a GPO contract requires engaging the GPO’s clinical and contracting review process. Warm introductions to hospital supply chain directors who serve on GPO advisory panels, or to GPO clinical committee members through existing clinical champions, can determine whether a company gains access to the committee review. A peer hospital administrator or department head who has already evaluated and deployed the device is the most credible reference for a GPO committee deliberation.
Does the Anti-Kickback Statute restrict how device companies can structure KOL relationships?
Yes. The Anti-Kickback Statute prohibits offering or paying anything of value to induce referrals of items covered by federal health programmes, which includes consulting fees, speaking honoraria, meals, and travel provided to physicians who could influence device selection. Safe harbours exist for bona fide consulting arrangements at fair market value with documented legitimate services, but device companies must structure KOL relationships carefully to fall within those safe harbours. The practical constraint is that all financial relationships with physicians need to be documented, at fair market value, and for services actually rendered, not as a mechanism for rewarding device adoption. Medical affairs and legal functions within device companies are deeply involved in reviewing and approving physician engagement structures for this reason.
Access the clinical and procurement networks that matter
LetsBridge connects you to the peer introductions that move medical device and healthcare BD conversations forward.